KCTD7 Polyclonal Antibody

Product Specifications

Background

Epilepsy affects about 0.5% of the world?s population and has a large genetic component. Epilepsy results from an electrical hyperexcitability in the central nervous system. Potassium channels are important regulators of electrical signaling, determining the firing properties and responsiveness of a variety of neurons. Benign familial neonatal convulsions (BFNC), an autosomal dominant epilepsy of infancy, has been shown to be caused by mutations in the KCNQ2 or the KCNQ3 potassium channel genes. KCNQ2 and KCNQ3 are voltage-gated potassium channel proteins with six putative transmembrane domains. Both proteins display a broad distribution within the brain, with expression patterns that largely overlap.

Synonyms

BTB/POZ domain containing protein KCTD7; EPM3; FLJ32069; Potassium channel tetramerisation domain containing 7; KCTD7_HUMAN.

Gene ID

154881

Swiss Prot

Q96MP8

Cellular Locus

Cytoplasm, Cell membrane

Host

Rabbit

Cross Reactivity

Human

Immunogen

112-180/289

Target

KCTD7

Clonality

Polyclonal

Conjugation

Unconjugated

Source

KLH conjugated synthetic peptide derived from human KCTD7

Applications

WB, ELISA, FCM, IHC-P, IHC-F, IF (IHC-P), IF (IHC-F), IF (ICC)

Purification

Purified by Protein A.

Concentration

1ug/ul

Dilution

WB (1:300-5000), ELISA (1:500-1000), FCM (1:20-100), IHC-P (1:200-400), IHC-F (1:100-500), IF (IHC-P) (1:50-200), IF (IHC-F) (1:50-200), IF (ICC) (1:50-200)